New study reveals genetic influence on cancer immune responsiveness
20 Feb 2021 - 10:28
The Peninsula
Doha: Sidra Medicine and Qatar Computing Research Institute (QCRI) at Hamad Bin Khalifa University (HBKU), Qatar Foundation, led a research study with the University of California San Francisco (UCSF) that represents a significant step toward personalised cancer immunotherapeutic approaches.
The international team of cancer immunologists, computational scientists, oncologists, biologists, and geneticists found that pre-existing anti-cancer immunity depends heavily on a patient’s genetic background. As such, certain genetic variants that make each of us unique can also influence the way the immune system fights tumors.
Immunotherapy, a therapeutic approach based on boosting the immune system, has changed the way cancer is treated, yet only a minority of patients respond to the treatment.
New study reveals genetic influence on cancer immune responsiveness
thepeninsulaqatar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thepeninsulaqatar.com Daily Mail and Mail on Sunday newspapers.
Qatar- New study reveals genetic influence on cancer immune responsiveness
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.
(MENAFN - Gulf Times) A multidisciplinary team of researchers and clinicians at Sidra Medicine, have launched a paediatric cancer biorepository pilot to develop personalised cancer therapies for patients.
Lead by Dr Wouter Hendrickx, Principal Investigator (PI) of the Paediatric Cancer Omics Lab and the Lead PI of the pilot, in close collaboration with Dr William Mifsud, Attending Physician from Sidra Medicine s Anatomic Pathology division, the biorepository is an integrated system that will collect patient samples and match complex data with clinical information.
Dr Wouter Hendrickx said, Personalised medicine is transitioning away from a one size fits all treatment approach towards a more advanced and detailed version, to better manage patients health. This not only helps manage the disease but also offers the best outcomes. The development of the biorepository pilot is a true showcase of how our research, pathology, patient care services have collaborated to offer the possi